Accretion Pharmaceuticals Ltd (ACCPL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039591,
    "name": "Accretion Pha.",
    "stock_name": "Accretion Pha.",
    "full_name": "Accretion Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/accretion-pha",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "92.45",
    "chg": 4.4,
    "chgp": "5.0%",
    "dir": 1,
    "prev_price": "88.05",
    "mcapval": "98.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "ACCPL",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0T8T01010",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 16800,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/accretion-pha-10039591-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Accretion Pha. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-accretion-pha-overvalued-or-undervalued-3713757",
        "imagepath": "",
        "date": "2025-11-19 08:12:39",
        "description": "As of 18 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 12.72, an EV to EBIT of 8.47, and a ROCE of 20.47%. \n\nIn comparison to its peers, Accretion Pharmaceuticals stands out with a significantly lower PE ratio than Sun Pharma (36.56) and Divi's Lab (69.17), both of which are considered expensive. Additionally, its EV to EBITDA ratio of 7.92 is more attractive compared to the higher ratios of its peers. The company's recent stock performance has also been notable, with a 1-week return of 29.5%, significantly outperforming the Sensex's return of 0.84%...."
      },
      {
        "title": "Is Accretion Pha. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-accretion-pha-overvalued-or-undervalued-3710252",
        "imagepath": "",
        "date": "2025-11-18 08:30:24",
        "description": "As of 17 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from very expensive to expensive, indicating a shift in market perception. The company is currently considered overvalued, with a PE ratio of 10.60, an EV to EBIT of 7.74, and an EV to EBITDA of 7.24. In comparison to its peers, Accretion's valuation metrics are significantly lower; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows even higher ratios at 69.78 and 52.44, respectively.\n\nDespite the high return on capital employed (ROCE) at 37.87% and a return on equity (ROE) of 44.42%, the overall valuation suggests that Accretion is not positioned favorably against its peers in the pharmaceuticals sector. Recent stock performance has outpaced the Sensex, with a 1-week return of 9.28% compared to the Sensex's 1.72%, which may reflect short-term investor enthusiasm but does no..."
      },
      {
        "title": "Is Accretion Pha. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-accretion-pha-overvalued-or-undervalued-3706185",
        "imagepath": "",
        "date": "2025-11-17 08:13:19",
        "description": "As of 14 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from expensive to very expensive. This indicates a shift towards a more negative outlook on the company's valuation. Based on the analysis, Accretion Pharmaceuticals is currently overvalued. The company has a PE ratio of 11.21, an EV to EBITDA of 7.59, and a PEG ratio of 0.00, which suggests that despite strong profitability metrics such as a ROCE of 37.87% and ROE of 44.42%, the valuation multiples are not justified when compared to its peers.\n\nIn comparison to its peers, Accretion's PE ratio is significantly lower than that of Sun Pharma, which stands at 36.49, and Divi's Lab at 69.65, both categorized as very expensive. Additionally, the EV to EBITDA ratio of 7.59 is lower than the ratios of Torrent Pharma at 33.11 and Divi's Lab at 52.35, reinforcing the notion that Accretion is overvalued relative to its industry. Furth..."
      },
      {
        "title": "Is Accretion Pha. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-accretion-pha-overvalued-or-undervalued-3705547",
        "imagepath": "",
        "date": "2025-11-16 08:13:03",
        "description": "As of 14 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from expensive to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 11.21, an EV to EBITDA of 7.59, and a Price to Book Value of 4.98. When compared to peers, Accretion's PE ratio is significantly lower than that of Sun Pharma (36.49) and Divi's Lab (69.65), both of which are classified as very expensive.\n\nDespite its strong return on equity (ROE) of 44.42% and return on capital employed (ROCE) of 37.87%, the high valuation grade suggests that the stock is priced excessively relative to its earnings potential. Recent performance shows Accretion's stock has outperformed the Sensex significantly over the past week with a return of 19.76% compared to the Sensex's 1.64%, but this does not mitigate the concerns regarding its current valuation...."
      },
      {
        "title": "Is Accretion Pha. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-accretion-pha-overvalued-or-undervalued-3704787",
        "imagepath": "",
        "date": "2025-11-15 08:12:40",
        "description": "As of 14 November 2025, the valuation grade for Accretion Pharma has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE Ratio of 11.21, an EV to EBITDA of 7.59, and a Price to Book Value of 4.98, which are notably high compared to its peers.\n\nIn comparison, Sun Pharma has a PE Ratio of 36.49 and an EV to EBITDA of 24.09, while Divi's Lab shows a PE Ratio of 69.65 and an EV to EBITDA of 52.35, both categorized as very expensive. This suggests that Accretion Pharma's valuation metrics, while high, are not as extreme as some of its competitors. Despite recent stock performance showing a 19.76% return over the past week compared to a 1.64% return for the Sensex, the overall valuation still points towards overvaluation in the current market context...."
      },
      {
        "title": "How has been the historical performance of Accretion Pha.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-accretion-pha-3704435",
        "imagepath": "",
        "date": "2025-11-15 00:39:23",
        "description": "Answer:\nThe historical performance of Accretion Pha. shows significant growth over the past three years, particularly from March 2024 to March 2025.\n\nBreakdown:\nAccretion Pha. experienced a substantial increase in net sales, rising from 13.35 Cr in March 2024 to 57.38 Cr in March 2025. This growth in total operating income was accompanied by a rise in raw material costs, which increased from 15.17 Cr to 43.71 Cr during the same period. The total expenditure also rose significantly, from 10.79 Cr to 45.50 Cr. However, the operating profit (PBDIT) improved markedly, reaching 11.97 Cr in March 2025, up from 2.61 Cr in March 2024. Profit before tax also saw a notable increase, climbing to 9.76 Cr from 2.00 Cr. Consequently, profit after tax surged to 6.79 Cr in March 2025, compared to 1.49 Cr in March 2024. The earnings per share (EPS) reflected this growth, increasing from 3.73 to 8.31. On the balance sheet, t..."
      }
    ],
    "total": 7,
    "sid": "10039591",
    "stock_news_url": "https://www.marketsmojo.com/news/accretion-pharmaceuticals-10039591"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Accretion Pha. overvalued or undervalued?

2025-11-19 08:12:39

As of 18 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 12.72, an EV to EBIT of 8.47, and a ROCE of 20.47%. In comparison to its peers, Accretion Pharmaceuticals stands out with a significantly lower PE ratio than Sun Pharma (36.56) and Divi's Lab (69.17), both of which are considered expensive. Additionally, its EV to EBITDA ratio of 7.92 is more attractive compared to the higher ratios of its peers. The company's recent stock performance has also been notable, with a 1-week return of 29.5%, significantly outperforming the Sensex's return of 0.84%....

Is Accretion Pha. overvalued or undervalued?

2025-11-18 08:30:24

As of 17 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from very expensive to expensive, indicating a shift in market perception. The company is currently considered overvalued, with a PE ratio of 10.60, an EV to EBIT of 7.74, and an EV to EBITDA of 7.24. In comparison to its peers, Accretion's valuation metrics are significantly lower; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows even higher ratios at 69.78 and 52.44, respectively. Despite the high return on capital employed (ROCE) at 37.87% and a return on equity (ROE) of 44.42%, the overall valuation suggests that Accretion is not positioned favorably against its peers in the pharmaceuticals sector. Recent stock performance has outpaced the Sensex, with a 1-week return of 9.28% compared to the Sensex's 1.72%, which may reflect short-term investor enthusiasm but does no...

Is Accretion Pha. overvalued or undervalued?

2025-11-17 08:13:19

As of 14 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from expensive to very expensive. This indicates a shift towards a more negative outlook on the company's valuation. Based on the analysis, Accretion Pharmaceuticals is currently overvalued. The company has a PE ratio of 11.21, an EV to EBITDA of 7.59, and a PEG ratio of 0.00, which suggests that despite strong profitability metrics such as a ROCE of 37.87% and ROE of 44.42%, the valuation multiples are not justified when compared to its peers. In comparison to its peers, Accretion's PE ratio is significantly lower than that of Sun Pharma, which stands at 36.49, and Divi's Lab at 69.65, both categorized as very expensive. Additionally, the EV to EBITDA ratio of 7.59 is lower than the ratios of Torrent Pharma at 33.11 and Divi's Lab at 52.35, reinforcing the notion that Accretion is overvalued relative to its industry. Furth...

Is Accretion Pha. overvalued or undervalued?

2025-11-16 08:13:03

As of 14 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from expensive to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 11.21, an EV to EBITDA of 7.59, and a Price to Book Value of 4.98. When compared to peers, Accretion's PE ratio is significantly lower than that of Sun Pharma (36.49) and Divi's Lab (69.65), both of which are classified as very expensive. Despite its strong return on equity (ROE) of 44.42% and return on capital employed (ROCE) of 37.87%, the high valuation grade suggests that the stock is priced excessively relative to its earnings potential. Recent performance shows Accretion's stock has outperformed the Sensex significantly over the past week with a return of 19.76% compared to the Sensex's 1.64%, but this does not mitigate the concerns regarding its current valuation....

Is Accretion Pha. overvalued or undervalued?

2025-11-15 08:12:40

As of 14 November 2025, the valuation grade for Accretion Pharma has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE Ratio of 11.21, an EV to EBITDA of 7.59, and a Price to Book Value of 4.98, which are notably high compared to its peers. In comparison, Sun Pharma has a PE Ratio of 36.49 and an EV to EBITDA of 24.09, while Divi's Lab shows a PE Ratio of 69.65 and an EV to EBITDA of 52.35, both categorized as very expensive. This suggests that Accretion Pharma's valuation metrics, while high, are not as extreme as some of its competitors. Despite recent stock performance showing a 19.76% return over the past week compared to a 1.64% return for the Sensex, the overall valuation still points towards overvaluation in the current market context....

How has been the historical performance of Accretion Pha.?

2025-11-15 00:39:23

Answer: The historical performance of Accretion Pha. shows significant growth over the past three years, particularly from March 2024 to March 2025. Breakdown: Accretion Pha. experienced a substantial increase in net sales, rising from 13.35 Cr in March 2024 to 57.38 Cr in March 2025. This growth in total operating income was accompanied by a rise in raw material costs, which increased from 15.17 Cr to 43.71 Cr during the same period. The total expenditure also rose significantly, from 10.79 Cr to 45.50 Cr. However, the operating profit (PBDIT) improved markedly, reaching 11.97 Cr in March 2025, up from 2.61 Cr in March 2024. Profit before tax also saw a notable increase, climbing to 9.76 Cr from 2.00 Cr. Consequently, profit after tax surged to 6.79 Cr in March 2025, compared to 1.49 Cr in March 2024. The earnings per share (EPS) reflected this growth, increasing from 3.73 to 8.31. On the balance sheet, t...

View All News